CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Wednesday reported a loss of $12.9 million in its fourth quarter.
On a per-share basis, the Chicago-based company said it had a loss of 10 cents.
The results surpassed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 16 cents per share.
The company posted revenue of $33.1 million in the period, also topping Street forecasts. Four analysts surveyed by Zacks expected $31 million.
For the year, the company reported a loss of $94.7 million, or 70 cents per share. Revenue was reported as $110.2 million.
Xeris Biopharma expects full-year revenue in the range of $135 million to $165 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on XERS at https://www.zacks.com/ap/XERS
Copyright © 2024 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
